Proactive Investors - Run By Investors For Investors

Paradigm Biopharmaceuticals director buys shares on-market

The company has today commenced the retail component of its $77.9 million capital raising.
man with briefcase running up ascending share price arrow
The non-executive director purchased the shares at an average price of $1.647

Paradigm Biopharmaceuticals Ltd (ASX:PAR) non-executive director Christopher Fullerton has purchased $32,130 worth of shares through on-market trades.

The 19,500-share purchase at an average price of $1.647 increases his overall holding to 855,500 shares.

Notably, this purchase price was done at a premium to the recent capital raising offer price of $1.50.

READ: Paradigm Biopharmaceuticals secures $61.3 million in first stage of raising

The capital raising will raise $77.9 million and comprised of a $61.3 million institutional component, which is complete, and a $16.6 million retail component which opens today.

Paradigm’s chairman Graeme Kaufman said in a letter to shareholders earlier this week: “It is anticipated that they will be applied, in conjunction with the Placement funds, to fund the company’s osteoarthritis and MPS (rare disease) programs through to end of their pivotal phase 3 studies, new drug applications, working capital, costs of offer, further preclinical studies and possibly further intellectual property acquisitions.”

View full PAR profile View Profile

Paradigm Biopharmaceuticals Ltd Timeline

Related Articles

September 29 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”
researcher at microscope
May 25 2019
Its lead asset, RXC004, is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use